Brought to you by 
Novartis, Vertex in kinase protein deal
May 2000
Executive Summary
Novartis Pharma and Vertex Pharmaceuticals signed an eight-year deal in which they will discover and develop small molecule therapeutics directed at targets in the kinase protein family. The deal is potentially worth $800mm.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
- Co-Promotion
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis, Vertex in kinase protein deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice